Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Adenocarcinoma of the Esophago-gastric Junction”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00032123
What this trial is testing

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal CancerGastric Cancer
SWOG Cancer Research Network
Large-scale testing (Phase 3)Active Not RecruitingNCT05078047
What this trial is testing

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Who this might be right for
Lung Cancer MetastaticRenal Cell CarcinomaHead and Neck Cancer+12 more
UNICANCER 646
Testing effectiveness (Phase 2)Active Not RecruitingNCT06628310
What this trial is testing

Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
AbbVie 185
Early research (Phase 1)Ended earlyNCT04144140
What this trial is testing

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Who this might be right for
LymphomaAdvanced Solid Tumors
Eisai Inc. 24
Testing effectiveness (Phase 2)Study completedNCT00045526
What this trial is testing

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Who this might be right for
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionRecurrent Esophageal Cancer+3 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)WithdrawnNCT06967987
What this trial is testing

Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b

Who this might be right for
Gastric and Gastro-oesophageal Junction (GEJ) AdenocarcinomasOverexpression FGFR2b
Institut Cancerologie de l'Ouest
Not applicableLooking for participantsNCT04850729
What this trial is testing

Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University 169
Testing effectiveness (Phase 2)UnknownNCT01359397
What this trial is testing

Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

Who this might be right for
Metastatic Gastric CancerAdenocarcinoma of the Gastro-oesophageal Junction
The Netherlands Cancer Institute
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06374888
What this trial is testing

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Who this might be right for
Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Convalife (Shanghai) Co., Ltd. 28
Testing effectiveness (Phase 2)Study completedNCT03283761
What this trial is testing

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Who this might be right for
Gastro-Esophageal Junction AdenocarcinomaGastric Cancer
Al B. Benson, III, MD 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT01512589
What this trial is testing

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

Who this might be right for
Esophageal Cancer
M.D. Anderson Cancer Center 147
Not applicableStudy completedNCT02305043
What this trial is testing

Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer

Who this might be right for
Esophageal NeoplasmsStomach Neoplasms
University of Leipzig 549
Not applicableStudy completedNCT03416101
What this trial is testing

Siewert Type II Esophageal Adenocarcinoma: Relationship Between Histology and Survival

Who this might be right for
Siewert Type II Adenocarcinoma of Esophagogastric Junction
University of Bologna 154
Testing effectiveness (Phase 2)Study completedNCT03126110
What this trial is testing

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Who this might be right for
Advanced MalignanciesMetastatic Cancer
Incyte Biosciences International Sàrl 145
Large-scale testing (Phase 3)Looking for participantsNCT07221149
What this trial is testing

Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Who this might be right for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb 690
Testing effectiveness (Phase 2)UnknownNCT00865982
What this trial is testing

Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer

Who this might be right for
Gastric CancerEsophageal Cancer
Charite University, Berlin, Germany 50
Testing effectiveness (Phase 2)Ended earlyNCT01271322
What this trial is testing

Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)

Who this might be right for
Adenocarcinomas of the Esophagogastric Junction
National Center for Tumor Diseases, Heidelberg
Testing effectiveness (Phase 2)Study completedNCT00107341
What this trial is testing

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Who this might be right for
Esophageal Cancer
Alliance for Clinical Trials in Oncology 37
Testing effectiveness (Phase 2)UnknownNCT05974059
What this trial is testing

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastric Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06680622
What this trial is testing

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Who this might be right for
Metastatic Gastro-esophageal Adenocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 126
Next Page